Atea Pharmaceuticals Updates On Global Phase 3 SUNRISE-3 Trial On Bemnifosbuvir For Treatment Of COVID-19; Says Trial Did Not Meet Primary Endpoint
Benzinga Newsdesk 2 years ago
News
The trial did not meet the primary endpoint of a statistically significant reduction in all-cause hospitalization or death through Day 29 in the monotherapy cohort of 2,221 high-risk patients with mild to moderate
The trial did not meet the primary endpoint of a statistically significant reduction in all-cause hospitalization or death through Day 29 in the monotherapy cohort of 2,221 high-risk patients with mild to moderate COVID-19. In SUNRISE-3, bemnifosbuvir was generally safe and well tolerated.